CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response

Abstract CDK4/6 inhibitors are standard of care in the treatment of metastatic breast cancer. Treatment regimen consists of a combination with endocrine therapy, since their therapeutic efficacy as monotherapy in most clinical trials was rather limited. Thus, understanding the molecular mechanisms t...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ting Hong, Anna C. Hogger, Dongbiao Wang, Qi Pan, Julie Gansel, Thomas Engleitner, Rupert Öllinger, Jürgen E. Gschwend, Roland Rad, Roman Nawroth
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Publishing Group 2024-10-01
Saila:	Cell Death Discovery
Sarrera elektronikoa:	https://doi.org/10.1038/s41420-024-02218-6
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!